See more : Yokohama Gyorui Co., Ltd. (7443.T) Income Statement Analysis – Financial Results
Complete financial analysis of SITE Centers Corp. (SITC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SITE Centers Corp., a leading company in the REIT – Retail industry within the Real Estate sector.
You may be interested
- ZUU Co.,Ltd. (4387.T) Income Statement Analysis – Financial Results
- Shinwa Co., Ltd. (3447.T) Income Statement Analysis – Financial Results
- S&B Foods Inc. (2805.T) Income Statement Analysis – Financial Results
- Kalyani Cast-Tech Limited (KALYANI.BO) Income Statement Analysis – Financial Results
- Asterisk Inc. (6522.T) Income Statement Analysis – Financial Results
SITE Centers Corp. (SITC)
About SITE Centers Corp.
SITE Centers is an owner and manager of open-air shopping centers that provide a highly-compelling shopping experience and merchandise mix for retail partners and consumers. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 546.28M | 540.81M | 492.34M | 416.76M | 447.75M | 654.86M | 879.45M | 969.51M | 995.10M | 953.77M | 888.79M | 800.38M | 771.02M | 803.07M | 819.31M | 931.47M | 944.85M | 818.10M | 727.18M | 598.93M | 476.10M | 357.24M | 322.24M | 285.79M | 263.93M | 228.17M | 169.04M | 130.91M | 108.60M | 81.80M | 51.70M |
| Cost of Revenue | 165.72M | 169.98M | 152.79M | 138.40M | 139.66M | 207.99M | 250.92M | 277.08M | 293.69M | 281.11M | 255.35M | 233.08M | 235.80M | 246.16M | 254.47M | 257.12M | 133.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 380.55M | 370.82M | 339.56M | 278.36M | 308.09M | 446.87M | 628.53M | 692.42M | 701.41M | 672.66M | 633.44M | 567.30M | 535.22M | 556.91M | 564.84M | 674.35M | 811.52M | 818.10M | 727.18M | 598.93M | 476.10M | 357.24M | 322.24M | 285.79M | 263.93M | 228.17M | 169.04M | 130.91M | 108.60M | 81.80M | 51.70M |
| Gross Profit Ratio | 69.66% | 68.57% | 68.97% | 66.79% | 68.81% | 68.24% | 71.47% | 71.42% | 70.49% | 70.53% | 71.27% | 70.88% | 69.42% | 69.35% | 68.94% | 72.40% | 85.89% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 50.87M | 46.56M | 55.05M | 52.88M | 58.38M | 61.64M | 89.85M | 76.10M | 73.38M | 84.48M | 79.56M | 76.44M | 85.22M | 85.57M | 94.37M | 97.72M | 81.24M | 60.68M | 54.05M | 47.13M | 40.82M | 29.39M | 24.38M | 20.45M | 17.77M | 12.92M | 11.06M | 8.44M | 6.40M | 5.60M | 4.10M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -15.36M | -15.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.87M | 46.56M | 55.05M | 52.88M | 58.38M | 61.64M | 89.85M | 76.10M | 73.38M | 84.48M | 79.56M | 76.44M | 85.22M | 85.57M | 79.00M | 81.88M | 81.24M | 60.68M | 54.05M | 47.13M | 40.82M | 29.39M | 24.38M | 20.45M | 17.77M | 12.92M | 11.06M | 8.44M | 6.40M | 5.60M | 4.10M |
| Other Expenses | 0.00 | 203.55M | 185.77M | 170.67M | 165.09M | 242.10M | -95.36M | 39.62M | 31.23M | 19.65M | -6.63M | -17.88M | 222.66M | 222.86M | 227.19M | 242.03M | 328.08M | 401.31M | 349.01M | 281.19M | 436.63M | 326.34M | 302.62M | 114.62M | 104.34M | 204.15M | 139.39M | 111.53M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 45.87M | 250.11M | 240.82M | 223.55M | 223.47M | 303.74M | 446.85M | 465.62M | 475.43M | 487.31M | 397.63M | 325.23M | 307.88M | 308.44M | 321.55M | 596.87M | 409.32M | 461.99M | 403.06M | 328.32M | 477.45M | 355.73M | 326.99M | 135.07M | 122.11M | 217.07M | 150.45M | 119.96M | -43.60M | -33.40M | -23.10M |
| Cost & Expenses | 430.47M | 420.09M | 393.61M | 361.95M | 363.13M | 511.73M | 697.77M | 742.70M | 769.12M | 768.42M | 652.99M | 558.30M | 543.67M | 554.60M | 576.02M | 596.87M | 542.66M | 461.99M | 403.06M | 328.32M | 477.45M | 355.73M | 326.99M | 135.07M | 122.11M | 217.07M | 150.45M | 119.96M | -43.60M | -33.40M | -23.10M |
| Interest Income | 0.00 | 0.00 | 0.00 | 11.89M | 18.01M | 20.44M | 28.36M | 37.05M | 29.21M | 15.93M | 23.54M | 15.80M | 9.83M | 7.35M | 12.11M | 5.47M | 8.81M | 0.00 | 0.00 | 0.00 | 5.08M | 5.91M | 6.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 82.00M | 77.69M | 77.03M | 77.60M | 84.72M | 141.31M | 188.65M | 217.59M | 241.73M | 237.12M | 228.87M | 221.42M | 229.72M | 226.46M | 237.94M | 244.21M | 258.15M | 0.00 | 0.00 | 0.00 | 240.26M | 101.97M | 92.37M | 100.83M | 87.40M | 77.92M | 67.52M | 49.54M | 25.50M | 21.20M | 8.60M |
| Depreciation & Amortization | 212.46M | 203.55M | 185.77M | 170.67M | 165.09M | 242.10M | 346.20M | 389.52M | 402.05M | 402.83M | 318.08M | 248.78M | 222.66M | 222.86M | 227.19M | 242.03M | 224.38M | 193.53M | 170.70M | 132.65M | 95.22M | 78.37M | 64.49M | 54.20M | 52.44M | 43.18M | 32.31M | 25.06M | 23.60M | 17.40M | 10.90M |
| EBITDA | 339.27M | 361.16M | 372.32M | 263.06M | 323.04M | 338.23M | 577.39M | 667.87M | 656.21M | 634.70M | 514.62M | 456.09M | 230.11M | 252.22M | 244.64M | 337.90M | 629.59M | 549.64M | 494.82M | 403.26M | 417.48M | 222.98M | 64.49M | 196.19M | 415.86M | 359.46M | 285.80M | 218.10M | 175.80M | 132.60M | 85.70M |
| EBITDA Ratio | 62.11% | 66.78% | 75.62% | 63.12% | 72.15% | 51.65% | 53.41% | 73.10% | 68.87% | 66.55% | 64.99% | 65.47% | 61.42% | 60.30% | 60.63% | 52.91% | 66.63% | 67.24% | 68.39% | 67.63% | 19.72% | 22.36% | 18.54% | 71.70% | 73.60% | 23.68% | 28.03% | 27.51% | 161.60% | 162.10% | 165.76% |
| Operating Income | 339.27M | 157.61M | 186.55M | 92.39M | 157.95M | 96.12M | 637.03M | 692.42M | 701.41M | 672.66M | 221.41M | 196.76M | 214.91M | 65.10M | -119.34M | 169.00M | 261.41M | 250.78M | 282.99M | 271.23M | 240.26M | 101.97M | 92.37M | 100.83M | 87.40M | 77.92M | 67.52M | 49.54M | 25.50M | 21.20M | 8.60M |
| Operating Income Ratio | 62.11% | 29.14% | 37.89% | 22.17% | 35.28% | 14.68% | 72.44% | 71.42% | 70.49% | 70.53% | 24.91% | 24.58% | 27.87% | 8.11% | -14.57% | 18.14% | 27.67% | 30.65% | 38.92% | 45.29% | 50.46% | 28.54% | 28.67% | 35.28% | 33.11% | 34.15% | 39.94% | 37.85% | 23.48% | 25.92% | 16.63% |
| Total Other Income/Expenses | -71.50M | -188.46M | -12.29M | -62.36M | -41.49M | -76.27M | -456.83M | -273.51M | -490.55M | -194.30M | -510.01M | -113.39M | -250.28M | -211.28M | -198.46M | -279.60M | -71.96M | -182.52M | -139.86M | -86.31M | 73.04M | -38.81M | -74.95M | -67.88M | 0.00 | -314.76M | -252.10M | 0.00 | -152.20M | 0.00 | 0.00 |
| Income Before Tax | 267.77M | 169.61M | 126.97M | 37.72M | 102.48M | -108.44M | -402.67M | -10.41M | -231.60M | 22.96M | 4.60M | -13.62M | -41.54M | -146.18M | -317.80M | -89.94M | 189.90M | 173.59M | 184.26M | 184.31M | 240.26M | 101.97M | 92.37M | 100.83M | 87.40M | 77.92M | 67.52M | 49.54M | 25.50M | 21.20M | 8.60M |
| Income Before Tax Ratio | 49.02% | 31.36% | 25.79% | 9.05% | 22.89% | -16.56% | -45.79% | -1.07% | -23.27% | 2.41% | 0.52% | -1.70% | -5.39% | -18.20% | -38.79% | -9.66% | 20.10% | 21.22% | 25.34% | 30.77% | 50.46% | 28.54% | 28.67% | 35.28% | 33.11% | 34.15% | 39.94% | 37.85% | 23.48% | 25.92% | 16.63% |
| Income Tax Expense | 2.05M | 816.00K | 1.55M | 1.13M | 659.00K | 862.00K | 1.62M | 1.78M | 6.29M | 1.86M | 2.71M | 1.16M | 1.04M | 47.99M | -691.00K | -17.43M | -14.64M | -2.48M | 342.00K | 1.47M | -240.26M | -101.97M | -92.37M | -100.83M | -87.40M | -77.92M | -67.52M | -49.54M | -25.50M | -21.20M | -8.60M |
| Net Income | 265.70M | 168.72M | 124.94M | 35.72M | 100.70M | -109.30M | -241.69M | 60.01M | -72.17M | 117.28M | -10.18M | -25.82M | -15.85M | -209.36M | -356.59M | -57.78M | 276.05M | 253.26M | 282.64M | 269.76M | 240.26M | 101.97M | 92.37M | 100.83M | 87.40M | 77.92M | 67.52M | 49.54M | 25.50M | 21.20M | 8.60M |
| Net Income Ratio | 48.64% | 31.20% | 25.38% | 8.57% | 22.49% | -16.69% | -27.48% | 6.19% | -7.25% | 12.30% | -1.14% | -3.23% | -2.06% | -26.07% | -43.52% | -6.20% | 29.22% | 30.96% | 38.87% | 45.04% | 50.46% | 28.54% | 28.67% | 35.28% | 33.11% | 34.15% | 39.94% | 37.85% | 23.48% | 25.92% | 16.63% |
| EPS | 4.85 | 2.96 | 2.04 | 0.74 | 2.20 | -2.37 | -5.26 | 1.31 | -1.60 | 2.00 | -0.25 | -0.72 | -0.47 | -6.84 | -17.96 | -3.48 | 13.41 | 13.12 | 15.14 | 16.37 | 16.66 | 11.55 | 12.07 | 12.95 | 10.27 | 9.89 | 7.43 | 6.06 | 4.61 | 4.83 | 2.74 |
| EPS Diluted | 4.85 | 2.92 | 2.04 | 0.74 | 2.20 | -2.37 | -5.26 | 1.31 | -1.60 | 2.00 | -0.25 | -0.72 | -0.47 | -6.84 | -17.96 | -3.47 | 13.34 | 13.05 | 15.00 | 16.15 | 16.37 | 11.34 | 11.97 | 12.95 | 9.96 | 9.50 | 7.43 | 5.99 | 4.61 | 4.76 | 2.74 |
| Weighted Avg Shares Out | 52.36M | 53.25M | 52.00M | 48.33M | 45.76M | 46.13M | 45.92M | 45.66M | 45.11M | 44.76M | 40.80M | 35.88M | 33.78M | 30.59M | 19.85M | 16.62M | 16.76M | 15.09M | 15.02M | 13.38M | 11.35M | 8.83M | 7.65M | 7.79M | 8.51M | 7.88M | 7.18M | 7.66M | 5.53M | 4.39M | 3.14M |
| Weighted Avg Shares Out (Dil) | 52.41M | 53.47M | 52.29M | 48.44M | 45.81M | 46.13M | 45.92M | 45.70M | 45.11M | 44.76M | 40.80M | 35.88M | 33.93M | 30.59M | 19.85M | 16.64M | 16.85M | 15.18M | 15.17M | 13.56M | 11.55M | 8.99M | 7.72M | 7.79M | 8.78M | 8.20M | 7.18M | 7.66M | 5.53M | 4.45M | 3.14M |
Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting
HONG KONG , Nov. 7, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926. HK) presented the mechanism of action (MOA)...
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune activation
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
Preliminary data demonstrate durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens
Strong Evidence of AU-007's Anti-Tumor Activity in Advanced Solid Tumor Cancers Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today shared positive results from its Phase 1/2 dose escalation and cohort expansion study of AU-007. The data will be presented...
Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting
– NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at week 8 – – Pharmacodynamic data show NKTR-255 increased NK cell proliferation and markers of NK cell...
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024.
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
- Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4 blockade -
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Presenting new clinical data from Phio's on-going Phase 1b trial Marlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its INTASYL® siRNA...
MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the...
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals -
Source: https://incomestatements.info
Category: Stock Reports